




オルメサルタン メドキソミル（日本薬局方記載条件）
Olmesartan Medoxomil (The Japanese Pharmacopoeia)

F150113K

Standard solution^{*1}(0.05 mg/mL Olmesartan medoxomil, 0.025 mg/mL *p*-Hydroxybenzoic acid isobutyl ester)

	System suitability requirement	Result
Resolution (1, 2)	≥4	9.4
Relative standard deviation of the peak area ratio of 1 to 2 (n=6)	≤0.5%	0.30%




Column	: YMC-Triart C18 ExRS (5 µm, 8 nm) 150 X 4.6 mmI.D.
Eluent	: phosphate buffer (pH 3.4) ^{*2} /acetonitrile (33/17) <i>*2 Dissolve 2.04 g of KH₂PO₄ in 1000 mL water, adjust pH to 3.4 with a solution of 1.73 g of phosphoric acid in 1000 mL water</i>
Flow rate	: 1.2 mL/min <i>(adjust the flow rate so that the retention time of olmesartan medoxomil is about 16 min)</i>
Temperature	: 40°C
Detection	: UV at 250 nm
Injection	: 10 µL
(The Japanese Pharmacopoeia 16th 2nd supplement; Assay)	

*1 Standard solution was prepared from Olmesartan medoxomil supplied as a reagent for laboratory use.



オルメサルタン メドキソミル錠（日本薬局方記載条件）

Olmesartan Medoxomil Tablets (The Japanese Pharmacopoeia)

F150113J

Standard solution^{*1}(0.04 mg/mL Olmesartan medoxomil, 0.01 mg/mL *p*-Hydroxybenzoic acid isobutyl ester)

	System suitability requirement	Result
Resolution (1, 2)	≥4	9.3
Relative standard deviation of the peak area ratio of 1 to 2 (n=6)	≤1.0%	0.85%

*p*-Hydroxybenzoic acid isobutyl ester (I.S.)

Column : YMC-Triart C18 ExRS (5 µm, 8 nm)
150 X 4.6 mmI.D.

Eluent : phosphate buffer (pH 3.4)^{*2}/acetonitrile (33/17)

^{*2} Dissolve 2.04 g of KH₂PO₄ in 1000 mL water, adjust pH to 3.4 with a solution of 1.73 g of phosphoric acid in 1000 mL water

Flow rate : 1.2 mL/min
(adjust the flow rate so that the retention time of olmesartan medoxomil is about 16 min)

Temperature : 40°C

Detection : UV at 250 nm


Injection : 10 µL

(The Japanese Pharmacopoeia 16th 2nd supplement; Assay)


*1 Standard solution was prepared from Olmesartan medoxomil supplied as a reagent for laboratory use.

オルメサルタン メドキソミル（米国薬局方記載条件）
Olmesartan Medoxomil (The United States Pharmacopeia)

F150119A


Standard solution^{*1}(0.05 mg/mL Olmesartan medoxomil, 0.025 mg/mL *p*-Hydroxybenzoic acid isobutyl ester)

System suitability requirement	Result
Resolution (1, 2)	≥4 10.1
Relative standard deviation of the peak area ratio of 1 to 2 (n=5)	≤0.5% 0.09%



Olmesartan medoxomil

2

*p*-Hydroxybenzoic acid isobutyl ester (I.S.)

Column : YMC-Triart C18 ExRS (5 µm, 8 nm)
150 X 4.6 mmI.D.

Eluent : 15 mM KH₂PO₄ buffer (pH 3.4)^{*2}/acetonitrile (33/17)
^{*2} Adjust pH to 3.4 with 0.2% (w/v) phosphoric acid

Flow rate : 1.0 mL/min

Temperature : 40°C

Detection : UV at 250 nm

Injection : 10 µL

(The United States Pharmacopeia 37th; Assay)

*1 Standard solution was prepared from Olmesartan medoxomil supplied as a reagent for laboratory use.